Pharmaxis Ltd (ASX:PXS – Get Rating) insider Gary Phillips acquired 1,640,450 shares of the firm's stock in a transaction dated Tuesday, November 1st. The stock was bought at an average cost of A$0.06 ($0.04) per share, with a total value of A$103,348.35 ($67,109.32).

Gary Phillips also recently made the following trade(s):

• On Monday, August 22nd, Gary Phillips 1,305,700 shares of Pharmaxis stock.

Pharmaxis Stock Performance

The company has a debt-to-equity ratio of 39.71, a quick ratio of 2.72 and a current ratio of 3.15.

About Pharmaxis

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma.

Further Reading

• New Revenue Strategy, Strong Earnings, Apple Remains a Buy
• Are Investors Bailing on Travel America as Diesel Shortages Loom?
• Devon Energy Lower After Beating Q3 Views But Slashing Dividend
• Chesapeake Energy Focus on Natural Gas Leads to Strong Results
• Sell-Side Interest Drives Mondelez Higher

Receive News & Ratings for Pharmaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmaxis and related companies with MarketBeat.com's FREE daily email newsletter.